Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain

Andrew D. Atiemo, Ladina S. Ng'Alla, Dhananjay Vaidya, Marlene Williams

Research output: Contribution to journalArticle

Abstract

Background: Antiplatelet therapy has been proven to be effective for both primary and secondary prevention of myocardial infarction, stroke, and cardiovascular death. However, a significant proportion of patients treated with aspirin experience ischemic events. A number of prospective studies have demonstrated that decreased responsiveness to antiplatelet therapy as measured by various methods, is strongly associated with an increase in clinical events. Our objective was to characterize platelet function in patients presenting with chest pain using a point-of-care assay, PFA-100® and correlating results to traditional platelet aggregometry to determine if patients with aspirin non-responsiveness have increased clinical sequelae. Methods: Platelet function was assessed using PFA-100®, flow cytometry, and optical aggregometry in 94 patients presenting to the emergency department with chest pain. All patients were on aspirin 81-325 mg daily. Clinical events occurring during the index hospitalization were documented. Results: Forty-seven patients (50%) were defined as aspirin non-responders by PFA-100® (collagen-epinephrine closure time ≤193). Compared to aspirin responders, aspirin non-responders had higher levels of mean platelet aggregation to adenosine diphosphate (ADP) (P = 0.004) and high dose epinephrine (P = 0.03). Furthermore, expression of PAC-1 was significantly increased in patients with aspirin nonresponse as compared to aspirin responders (P = 0.003 and P = 0.0006 respectively). No significant difference in clinical events during the index hospitalization was noted between aspirin non-responders and aspirin responders. Conclusion: Patients presenting with chest pain who have abnormal PFA-100 closure times have increased platelet aggregation and activation however this aspirin non-responsiveness does not correlate with increased clinical events in the index hospitalization.

Original languageEnglish (US)
Pages (from-to)173-178
Number of pages6
JournalJournal of Thrombosis and Thrombolysis
Volume25
Issue number2
DOIs
StatePublished - Apr 2008

Fingerprint

Chest Pain
Platelet Aggregation
Aspirin
Hospitalization
Blood Platelets
Epinephrine
Point-of-Care Systems
Myocardial Infarction
Platelet Activation
Primary Prevention
Secondary Prevention
Adenosine Diphosphate
Hospital Emergency Service
Flow Cytometry
Collagen
Prospective Studies

Keywords

  • Antiplatelet therapy
  • Aspirin nonresponse
  • Coronary artery disease
  • Platelets

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain. / Atiemo, Andrew D.; Ng'Alla, Ladina S.; Vaidya, Dhananjay; Williams, Marlene.

In: Journal of Thrombosis and Thrombolysis, Vol. 25, No. 2, 04.2008, p. 173-178.

Research output: Contribution to journalArticle

@article{8d30f1ca7b3740159b6f510f77fc7cb7,
title = "Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain",
abstract = "Background: Antiplatelet therapy has been proven to be effective for both primary and secondary prevention of myocardial infarction, stroke, and cardiovascular death. However, a significant proportion of patients treated with aspirin experience ischemic events. A number of prospective studies have demonstrated that decreased responsiveness to antiplatelet therapy as measured by various methods, is strongly associated with an increase in clinical events. Our objective was to characterize platelet function in patients presenting with chest pain using a point-of-care assay, PFA-100{\circledR} and correlating results to traditional platelet aggregometry to determine if patients with aspirin non-responsiveness have increased clinical sequelae. Methods: Platelet function was assessed using PFA-100{\circledR}, flow cytometry, and optical aggregometry in 94 patients presenting to the emergency department with chest pain. All patients were on aspirin 81-325 mg daily. Clinical events occurring during the index hospitalization were documented. Results: Forty-seven patients (50{\%}) were defined as aspirin non-responders by PFA-100{\circledR} (collagen-epinephrine closure time ≤193). Compared to aspirin responders, aspirin non-responders had higher levels of mean platelet aggregation to adenosine diphosphate (ADP) (P = 0.004) and high dose epinephrine (P = 0.03). Furthermore, expression of PAC-1 was significantly increased in patients with aspirin nonresponse as compared to aspirin responders (P = 0.003 and P = 0.0006 respectively). No significant difference in clinical events during the index hospitalization was noted between aspirin non-responders and aspirin responders. Conclusion: Patients presenting with chest pain who have abnormal PFA-100 closure times have increased platelet aggregation and activation however this aspirin non-responsiveness does not correlate with increased clinical events in the index hospitalization.",
keywords = "Antiplatelet therapy, Aspirin nonresponse, Coronary artery disease, Platelets",
author = "Atiemo, {Andrew D.} and Ng'Alla, {Ladina S.} and Dhananjay Vaidya and Marlene Williams",
year = "2008",
month = "4",
doi = "10.1007/s11239-007-0045-5",
language = "English (US)",
volume = "25",
pages = "173--178",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain

AU - Atiemo, Andrew D.

AU - Ng'Alla, Ladina S.

AU - Vaidya, Dhananjay

AU - Williams, Marlene

PY - 2008/4

Y1 - 2008/4

N2 - Background: Antiplatelet therapy has been proven to be effective for both primary and secondary prevention of myocardial infarction, stroke, and cardiovascular death. However, a significant proportion of patients treated with aspirin experience ischemic events. A number of prospective studies have demonstrated that decreased responsiveness to antiplatelet therapy as measured by various methods, is strongly associated with an increase in clinical events. Our objective was to characterize platelet function in patients presenting with chest pain using a point-of-care assay, PFA-100® and correlating results to traditional platelet aggregometry to determine if patients with aspirin non-responsiveness have increased clinical sequelae. Methods: Platelet function was assessed using PFA-100®, flow cytometry, and optical aggregometry in 94 patients presenting to the emergency department with chest pain. All patients were on aspirin 81-325 mg daily. Clinical events occurring during the index hospitalization were documented. Results: Forty-seven patients (50%) were defined as aspirin non-responders by PFA-100® (collagen-epinephrine closure time ≤193). Compared to aspirin responders, aspirin non-responders had higher levels of mean platelet aggregation to adenosine diphosphate (ADP) (P = 0.004) and high dose epinephrine (P = 0.03). Furthermore, expression of PAC-1 was significantly increased in patients with aspirin nonresponse as compared to aspirin responders (P = 0.003 and P = 0.0006 respectively). No significant difference in clinical events during the index hospitalization was noted between aspirin non-responders and aspirin responders. Conclusion: Patients presenting with chest pain who have abnormal PFA-100 closure times have increased platelet aggregation and activation however this aspirin non-responsiveness does not correlate with increased clinical events in the index hospitalization.

AB - Background: Antiplatelet therapy has been proven to be effective for both primary and secondary prevention of myocardial infarction, stroke, and cardiovascular death. However, a significant proportion of patients treated with aspirin experience ischemic events. A number of prospective studies have demonstrated that decreased responsiveness to antiplatelet therapy as measured by various methods, is strongly associated with an increase in clinical events. Our objective was to characterize platelet function in patients presenting with chest pain using a point-of-care assay, PFA-100® and correlating results to traditional platelet aggregometry to determine if patients with aspirin non-responsiveness have increased clinical sequelae. Methods: Platelet function was assessed using PFA-100®, flow cytometry, and optical aggregometry in 94 patients presenting to the emergency department with chest pain. All patients were on aspirin 81-325 mg daily. Clinical events occurring during the index hospitalization were documented. Results: Forty-seven patients (50%) were defined as aspirin non-responders by PFA-100® (collagen-epinephrine closure time ≤193). Compared to aspirin responders, aspirin non-responders had higher levels of mean platelet aggregation to adenosine diphosphate (ADP) (P = 0.004) and high dose epinephrine (P = 0.03). Furthermore, expression of PAC-1 was significantly increased in patients with aspirin nonresponse as compared to aspirin responders (P = 0.003 and P = 0.0006 respectively). No significant difference in clinical events during the index hospitalization was noted between aspirin non-responders and aspirin responders. Conclusion: Patients presenting with chest pain who have abnormal PFA-100 closure times have increased platelet aggregation and activation however this aspirin non-responsiveness does not correlate with increased clinical events in the index hospitalization.

KW - Antiplatelet therapy

KW - Aspirin nonresponse

KW - Coronary artery disease

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=42549172230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42549172230&partnerID=8YFLogxK

U2 - 10.1007/s11239-007-0045-5

DO - 10.1007/s11239-007-0045-5

M3 - Article

VL - 25

SP - 173

EP - 178

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 2

ER -